Video
Dr. Hensing Discusses Studies in Stage III NSCLC
Author(s):
Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non-small cell lung cancer (NSCLC).
Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non—small cell lung cancer (NSCLC).
Hensing says that the most exciting prospective study in stage III NSCLC is the PACIFIC trial, which evaluated durvalumab (Imfinzi) following concurrent chemoradiation.
The progression-free survival Kaplan-Meier curve in this trial was the first time an improvement in outcome was observed for patients with stage III disease.
Related Videos
Related Content
